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ABSTRACT
Objective Micro-RNAs (miRNAs) play a crucial role in
controlling intestinal epithelial barrier function partly by
modulating the expression of tight junction (TJ) proteins. We
have previously shown differential messenger RNA (mRNA)
expression correlated with ultrastructural abnormalities of
the epithelial barrier in patients with diarrhoea-predominant
IBS (IBS-D). However, the participation of miRNAs in these
differential mRNA-associated findings remains to be
established. Our aims were (1) to identify miRNAs
differentially expressed in the small bowel mucosa of
patients with IBS-D and (2) to explore putative target genes
specifically involved in epithelial barrier function that are
controlled by specific dysregulated IBS-D miRNAs.
Design Healthy controls and patients meeting Rome III
IBS-D criteria were studied. Intestinal tissue samples were
analysed to identify potential candidates by: (a) miRNA-
mRNA profiling; (b) miRNA-mRNA pairing analysis to assess
the co-expression profile of miRNA-mRNA pairs; (c) pathway
analysis and upstream regulator identification; (d) miRNA
and target mRNA validation. Candidate miRNA-mRNA pairs
were functionally assessed in intestinal epithelial cells.
Results IBS-D samples showed distinct miRNA and
mRNA profiles compared with healthy controls. TJ
signalling was associated with the IBS-D transcriptional
profile. Further validation of selected genes showed
consistent upregulation in 75% of genes involved in
epithelial barrier function. Bioinformatic analysis of putative
miRNA binding sites identified hsa-miR-125b-5p and hsa-
miR-16 as regulating expression of the TJ genes CGN
(cingulin) and CLDN2 (claudin-2), respectively. Consistently,
protein expression of CGN and CLDN2 was upregulated in
IBS-D, while the respective targeting miRNAs were
downregulated. In addition, bowel dysfunction, perceived
stress and depression and number of mast cells correlated
with the expression of hsa-miR-125b-5p and hsa-miR-16
and their respective target proteins.
Conclusions Modulation of the intestinal epithelial
barrier function in IBS-D involves both transcriptional and
post-transcriptional mechanisms. These molecular
mechanisms include miRNAs as master regulators in
controlling the expression of TJ proteins and are associated
with major clinical symptoms.
Significance of this study
What is already known on this subject?
▸ Differential messenger RNA (mRNA) signatures
correlate with ultrastructural abnormalities in
the intestinal epithelial barrier in patients with
diarrhoea-predominant IBS (IBS-D).
▸ A distinctive micro-RNA (miRNA) expression
profile has been identified both in the intestinal
mucosa and in the peripheral blood of patients
with IBS-D.
▸ However, combined high-throughput analysis of
the expression of miRNA and mRNA profiles in
the jejunal mucosa has not been performed.
What are the new findings?
▸ We provide evidence of miRNA-dependent
modulation of tight junction-specific proteins
by using an integrative approach combining
both mRNA expression data from RNA
sequencing analysis and miRNA expression
profiles in the jejunum of patients with IBS-D.
▸ Expression of hsa-miR-125b-5p and hsa-miR-16
is downregulated while their respective target
proteins, cingulin and claudin-2 are
upregulated.
▸ Functional analysis of the role of hsa-miR-125b-
5p and hsa-miR-16 identified these miRNAs as
modulators of barrier function.
▸ These molecular alterations correlated with bowel
dysfunction, perceived stress and depression and
with number of mucosal mast cells.
How might it impact on clinical practice in
the foreseeable future?
▸ Defining the complex array of interactions of
miRNAs with apical junctional proteins will pave
the way for potential diagnostic and therapeutic
interventions that would reinforce the intestinal
barrier function, consequently preventing or
ameliorating inflammatory reactions.
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INTRODUCTION
IBS has traditionally been considered as a functional GI disorder
defined by clinical manifestations lacking specific and sensitive
biological markers. However, recent cumulative evidence high-
lights the plausible organic origin of IBS symptoms. Particularly,
distorted mucosal barrier ultrastructure,1–4 immune activation
and low-grade inflammation5–9 have been implicated in IBS.
Latest studies have shown differential expression of genes
related to alterations in immune system signalling pathways and
intestinal barrier function.10–12 In addition, our group has lately
described differential mucosal humoral activation and transcrip-
tional signatures correlated with ultrastructural abnormalities in
the epithelial barrier associated with mast cell activation and
major clinical manifestations in patients with diarrhoea-
predominant IBS (IBS-D).1 13 14
Previous studies have mainly focused on the expression of
protein-coding genes and their correlation to clinical outcomes.
As a matter of fact, <3% of the human genome encode pro-
teins,15 consequently, the majority of the transcribed human
genome represents non-coding RNAs.16 17 Among them,
micro-RNAs (miRNAs) are particularly relevant for intestinal
inflammatory disorders as recent research reported on their
impact in the regulation of immune and inflammatory
responses.18 19 To date, their role in IBS has been addressed
only in a few studies. The first evidence for a miRNA-regulated
expression of serotonin (5-HT) receptor genes in IBS20 21 was
reported as association of IBS-D with gene variants residing in
regulatory regions causing disturbed regulation by hsa-miR-510
and hsa-miR-16 family. The respective variants seem to impair
miRNA binding to the target region, thereby reducing transla-
tional repression and increasing protein expression. More recent
studies have reported distinctive miRNA profiles in IBS-D ana-
lysing the intestinal mucosa22 and peripheral blood.23 The role
of miRNA-driven expression regulation in the gut is underlined
by a study investigating the relevance of miRNAs during devel-
opment, differentiation and function of the intestinal epithelium
in a knockout mouse of the pre-miRNA processing enzyme
Dicer1.24 Of note, Dicer1-deficient animals showed significant
changes in miRNA profiles correlating with a remarkable disor-
ganisation of the gut epithelium, impairment of the intestinal
barrier and intestinal inflammation.24
Therefore, we hypothesised that miRNA-driven dysregulation
of intestinal immune system activation and epithelial barrier
function is involved in the pathophysiology of IBS-D. Our spe-
cific aims were to identify miRNAs differentially expressed in
the small bowel of patients with IBS-D compared with healthy
controls (HC) and to identify target proteins specifically
involved in intestinal epithelial barrier function. We applied the
following multistage strategy: (1) identification of differentially
expressed miRNAs and their target transcripts in patients with
IBS-D versus HC by RNA sequencing (RNAseq) and miRNA
profiling; (2) ascertainment of regulatory networks, biological
functions and upstream regulators associated with the potential
targets identified in the previous approach by pathway analysis
and (3) investigation of the functional relevance of specific
miRNA’s modulation of endogenous protein expression and epi-
thelial barrier function in intestinal epithelial cell lines.
METHODS
Participants
Newly diagnosed patients meeting Rome III IBS-D criteria25
and HC were prospectively recruited from the gastroenterology
outpatient clinic (see also online supplementary methods
section). HC were recruited from the general population by
public advertising. Prior to entering the study, a complete
medical history and physical examination were carried out in
both patients and controls. All subjects completed structured
clinical questionnaires (to characterise digestive symptoms in
patients and to verify the lack of symptoms in HC) and under-
went allergy tests to rule out food allergy (see below). Healthy
subjects reporting abdominal symptoms were excluded from the
study. In addition, past episodes of infectious gastroenteritis and
GI comorbidities were reasonably excluded by performing a
broad biochemical and serologic profile including antitransgluta-
minase antibodies, upper and lower fibre optic and small bowel
capsule endoscopy, abdominal sonography and barium studies,
when considered pertinent. The study protocol was approved
by the Ethics Committee at the Hospital Vall d’Hebron (PR(AG)
159/2011). Written informed consent was obtained from each
participant.
Using daily questionnaires over a 10-day period, the following
parameters were recorded: (a) severity of abdominal pain by a
100-point visual analogue scale; (b) frequency of abdominal
pain (number of days with pain); (c) stool frequency (day with
maximum number of bowel movements) and (d) stool consist-
ency assessed by the Bristol stool form score.26 Background
stress and depression levels were evaluated using the validated
Spanish versions of the Modified Social Readjustment Scale of
Holmes-Rahe,27 by the Perceived Stress Scale of Cohen28 and
by the Beck’s Inventory for Depression.29
Skin prick tests (SPT) were performed with 22 common food
allergens (Laboratorios Leti, Barcelona, Spain), using histamine
and saline as positive and negative controls, respectively.
Positivity was defined by skin weal reaction (diameter >3 mm)
to at least one allergen. Candidates with either positivity to
foodstuff by SPT or clinical history consistent with food allergy
(digestive and/or extradigestive symptoms associated with expos-
ure to certain food components) were excluded.
Experimental design and procedures
To investigate the role of differentially expressed miRNAs and
messenger RNAs (mRNAs) in the aetiopathology of IBS, total
RNA isolated from gut biopsies of IBS-D and HC was subjected
to next-generation sequencing. Tissue samples were obtained as
follows: a single mucosal biopsy per participant was obtained
from the proximal jejunum, 5–10 cm distal to the Treitz’s angle,
using a Watson’s capsule as described previously.5 Tissue
samples were immediately split into two similar pieces with a
sterile scalpel. One fragment was fixed in formalin and embed-
ded in paraffin for further microscopic examination assessing
inflammation by routine procedures and mast cell numbers by
CD117 staining. The remaining fragment was placed in
RNAse-free tubes containing 500 μL of RNA Later Solution
(Life Technologies) and stored at −80°C until processed for
RNA and protein isolation.
Eighty-five subjects were initially recruited. Five samples from
the healthy control group were excluded due to abnormal
results (>40 intraepithelial lymphocytes) on routine histology.
After RNA isolation, 11 subjects were also excluded due to
insufficient RNA quality (RNA integrity number (RIN) <5).
Therefore, a total of 69 subjects (43 patients with IBS-D and 26
HC) were finally included in the study. The following analyses
were subsequently performed in blindly selected subgroups of
subjects (see online supplementary figure S1 and table S1). The
selection of subjects for the mRNA-miRNA discovery cohort
was made only among those samples showing a RIN value >8.
The selection of samples for the other analyses was then made
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based on RNA/protein availability. Detailed description of pro-
cedures is given in the online supplementary methods section.
mRNA and miRNA profiling
Total RNA was isolated from jejunal biopsies of a discovery
cohort comprising eight patients with IBS-D and eight HC.
Then, isolated RNAwas analysed as follows:
A. mRNA expression was assessed by RNAseq on an Illumina
Hi-Seq 2000.
B. miRNA expression was assessed by two different technolo-
gies: nCounter analysis system (Human_v2_miRNA expres-
sion assay kit, from miRBase v14.0) and Agilent microarrays
(Agilent’s Unrestricted_Human_miRNA_V16.0).
Pathway analysis
To identify relevant biological pathways implicating those genes
differentially expressed, we applied ingenuity pathway analysis
(IPA) methodology (IPA Software, Ingenuity Systems, http://
www.ingenuity.com). IPA integrates selected omics data sets
(genomics, transcriptomics, miRNAomics, proteomics) with
mining techniques to predict functional connections and their
interpretation in the context of protein networks that comprise
protein-protein interactions and related biological functions and
canonical signalling pathways. Two types of analysis were
performed in our profiling data (see online supplementary
figure S2):
A. mRNA and miRNA core analysis to identify the biological
functions of the differentially expressed miRNA-target genes
followed by identification of putative upstream regulators.
B. miRNA target filter plus miRNA-mRNA pairing analysis in
order to identify coregulated miRNA-target mRNA pairs.
Validation of profiling results
A. Quantitative PCR (qPCR) was used to validate miRNA pro-
filing results and to assess expression of additional miRNAs
identified in subsequent pathway analysis in samples from
14 IBS-D versus 18 HC.
B. A customised nCounter Gene Expression CodeSet was used
in order to validate results obtained by RNAseq in add-
itional jejunal RNA samples from 31 IBS-D versus 17 HC.
This CodeSet included oligonucleotide probes for detection
of genes involved in epithelial barrier function (see online
supplementary table S2).
C. Further validation of results at the protein level was per-
formed by western blot analysis in 25 patients with IBS-D
versus 15 HC. Antibodies used can be found in online
supplementary table S3.
In addition, molecular changes were correlated with major clin-
ical and histopathological features of patients.
Functional analysis
A. The functional interaction between specific miRNA candi-
dates and their respective putative target genes was assessed
by overexpression and inhibition of candidate miRNAs in a
human intestinal epithelial cell line, colo320. Candidate
miRNAs and their respective mutants harbouring disrupted
seed sequences were cloned into pEP-miR expression vectors
and transfected into colo320 cells. Detailed information on
the cloning strategy can be found in online supplementary
table S4. Endogenous levels of putative target proteins were
measured by In-Cell Western (ICW) analysis (see online
supplementary table S3).
B. The impact of candidate miRNAs on epithelial barrier func-
tion was assessed using the T84 cell line as a well-established
model for human intestinal epithelia cells. This human
colon cell line is able to polarise and establish fully func-
tional tight junctions (TJs) in vitro when seeded on transwell
inserts.30 Due to the low efficiency and short-term effect of
the transient transfection of plasmids, we used a lentivirus-
mediated expression system and subsequently selected T84
cells, where hsa-miR-125b-5p and hsa-miR-16 are either
stably overexpressed or downregulated by respective
miRNA-sponges (molecules loaded with a multitude of
respective complementary miRNA binding sites, acting as
competitive inhibitors of miRNAs).31 The created stable
T84 cells were then seeded on collagen-coated transwells
and the permeability of the epithelial layer was assessed by
measuring transepithelial electrical resistance (TEER) every
day for 7 days. Polarisation and formation of TJs was also
controlled by immunostaining of the established TJ protein
marker zonula occludens 1 (ZO1). After overexpression or
downregulation of the candidate miRNAs, endogenous
levels of putative target proteins were measured by western
blot analysis. Additionally, the structure of TJs was also
assessed by counting the number of nuclei surrounded by
the belt of ZO1.
Statistical analysis
Statistical analysis of miRNA profiling data
miRNA expression values were normalised to take into account
possible batch effects and intersample variability. The median
absolute deviation (MAD) of expression values over all samples
was calculated for each miRNA. miRNAs showing the 5%
lowest MADs, and miRNAs with missing values for some
samples were excluded from further analyses. Wilcoxon two-
sided rank tests were applied to identify miRNAs with a differ-
ential expression in the two groups of samples. miRNAs with
corresponding p values <0.05 were followed-up (see online
supplementary material). Biostatistical analyses were conducted
using R V.2.15.2 (R Development Core Team).
Statistical analysis for mRNA profiling data
RNAseq reads were aligned to the reference genome of Homo
sapiens version GRCh37 (ENSEMBL based) obtained from
iGenomes (https://ccb.jhu.edu/software/tophat/igenomes.html).
No prior filtering of sequencing data was applied since anomal-
ous reads were automatically discarded by the alignment pro-
gramme. Total reads per sample ranged from 18 to 43.5
million. Only mRNAs with mean normalised read counts above
100 were investigated. The differential expression analysis was
then performed using the Bioconductor package DESeq2.32
Normalisation was performed using the package defaults by
computing sample-specific size factors to control for batch
effects and other biases present in the data. Empirical distribu-
tion functions for the normalised counts showed no systematic
differences across samples. Gene level count tables were
obtained using the count script of the HTSeq python library.
Raw p values from a negative binomial distribution were calcu-
lated by DESeq2 and they were used as input to fdrtool in
order to compute q-values (false discovery rates (FDRs)). Genes
with a FDR <0.1 were considered differentially expressed (see
online supplementary material).
Statistical analysis for qPCR, western blot, ICW and
immunofluorescence data
Two-tailed parametric or non-parametric tests were used as
appropriate (unpaired Student’s t-test, Mann-Whitney U test,
two-way analysis of variance followed by Bonferroni post-tests)
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using GraphPad Prism 5.0 software. Relationships between clin-
ical variables and gene expression were assessed by Spearman’s
correlation rho. Data are summarised by mean±SD, unless other-
wise stated. Adjustment for multiplicity was carried out using
objective-specific methods. FDRs were calculated to identify the
list of genes/miRNAs used as input for pathway analyses using the
Benjamini and Hochberg method.33 Bonferroni-adjusted prob-




We found no differences in age, gender proportion or body
mass index between patients and controls (table 1). Patients
showed significantly higher frequency of dyspepsia and scores of
perceived stress and depression than HC (table 1). No differ-
ences in disease severity between discovery and validation
cohorts was found (p=0.42). Furthermore, subgroups did not
differ in clinical characteristics of applied biological assessments
(p>0.23 for all) (see online supplementary table S5).
Specific genes are differentially expressed in the jejunal
mucosa of patients with IBS-D
On average, ∼29 million reads were obtained for each sample
and, the average mapping rate to the human genome was
∼80%. A total of ∼10 million reads were excluded for further
analysis due to different reasons (not showing unique align-
ments, alignment was ambiguous or not overlapping any gene
features) leading to ∼14 million reads that were used as the
basis for counting. The counts were then normalised and filtered
rendering ∼15 000 mRNAs. Differential expression analysis was
then performed by DESeq2, which identified 3806 mRNAs dif-
ferentially expressed (mean normalised read counts >100; FDR
<0.05) in IBS-D versus HC. IPA analysis identified a number of
canonical signalling pathways key for intestinal homeostasis as
playing an important role in IBS-D (table 2).
As a proof of principle, and to validate earlier findings of
impaired barrier function, genes related to the TJ signalling
pathway were selected and subsequently analysed by the
nCounter technology in a larger patient cohort (IBS-D, n=37;
HC, n=17). Similar results were obtained by both techniques
(table 3). In addition, no differences in the expression of any of
these genes were found comparing patients with and without
functional dyspepsia (see online supplementary table S6).
The jejunal mucosa of patients with IBS-D shows a
distinctive miRNA expression signature
Data from miRNA profiling was used for network analysis by
IPA. The most significant network identified was composed of
eight miRNAs differentially expressed in IBS-D samples com-
pared with HC (FDR <0.05) linked to their respective target
proteins (figure 1). In this network, hsa-miR-125b-5p was iden-
tified playing a central role by targeting proteins involved in
pathways related to the epithelial barrier function like apoptosis
of epithelial cells, TJ and actin-cytoskeleton signalling pathways
(figure 1). These functions were also highlighted by RNAseq
data (table 2).
miRNA-mRNA pairing analysis identified intestinal
epithelial-related functions and humoral immune response
as potentially dysregulated in the jejunal mucosa of
patients with IBS-D
In order to narrow down the list of relevant distinctive molecu-
lar targets playing a role in IBS-D, target filter analysis and
miRNA-mRNA pairing was performed combining both differen-
tially expressed mRNAs and miRNAs. This analysis identified
1393 mRNAs that were experimentally observed or predicted
with a moderate/high score to be targets of differentially
expressed miRNAs in IBS-D. The top molecular functions asso-
ciated with the target genes included apoptosis of epithelial cells
and several functions related to the architecture and disorganisa-
tion of apical junctional complexes and the humoral immune
response (table 4). These results confirm our previous findings
from different sample cohorts.1 13 14
Moreover, to further validate the biological relevance of our
results, IPA was used to identify particular miRNAs that may
explain the observed mRNA differential expression in patients
Table 1 Clinical and demographic characteristics of participants
IBS-D
(n=43) HC (n=26) p Value
Age, years 35 (20–60) 32 (23–58) 0.38
Gender, M:F 17:26 12:14 0.77
Body mass index 23.3±3.6 23.0±3.1 0.74
Functional dyspepsia 23/43 0/26 –
Severity of the disease, Francis
score
252.9±88.2 – –
Abdominal pain intensity, score 41.7±23.6 – –
Abdominal pain frequency, number
of days
6 (2–10) – –
Bowel movements, number/day 3.4±1.4 1.5±0.6 <0.0001***
Stool form, Bristol score 6 (2–7) 3.5 (3–5) <0.0001***





Cohen scale 23.7±7.0 17.1±7.3 0.0003**
Beck’s index 8 (0–32) 0 (0–10) <0.0001***
Values represent median (range) or mean±SD.
p Values considered significant are shown in bold: **<0.001; ***<0.0001.
F, female; M, male; HC, healthy controls; IBS-D, diarrhoea-predominant IBS.
Table 2 Canonical signalling pathways associated with IBS-D
gene expression profile
Ingenuity canonical signalling pathways FDR Ratio*
PTEN signalling 0.00005 0.35
Axonal guidance signalling 0.0002 0.25
PI3K/AKT signalling 0.0005 0.32
ERK/MAPK signalling 0.0006 0.29
B-cell receptor signalling 0.002 0.28
Tight junction signalling 0.008 0.27
Caveolar-mediated endocytosis signalling 0.02 0.31
Actin cytoskeleton signalling 0.04 0.24
Epithelial adherens junction signalling 0.04 0.25
NF-κB signalling 0.04 0.24
p38 MAPK signalling 0.05 0.26
Regulation of actin-based motility by rho 0.08 0.26
Role of NFAT in regulation of the immune response 0.10 0.23
Antigen presentation pathway 0.38 0.24
*Ratio: number of genes in the analysis that are associated with the canonical
pathway divided by the total number of genes that map to the canonical pathway.
PTEN, phosphatase and tensin homologue deleted on chromosome ten; PI3K/AKT,
phosphoinositide-3-kinase/v-akt murine thymoma viral oncogene homologue 1; ERK/
MAPK, extracellular signal-regulated kinase/mitogen-activated protein kinase; NF-κB,
nuclear factor κB; NFAT, nuclear factor of activated T cells; FDR, false discovery rate,
p values are adjusted for multiple testing by the Benjamini and Hochberg method.
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with IBS-D, so called by IPA as upstream regulators. In this ana-
lysis, hsa-miR-125b-5p and hsa-miR-16-5p were identified as
the most significantly deregulated miRNAs predicted to be
inhibited based on the expression pattern of their targets
(table 5). Downregulation of both miRNAs in IBS-D samples
was then validated by qPCR (figure 2A).
CGN and CLDN2 are targets of hsa-miR-125b-5p and
hsa-miR-16
Based on the previous results, we decided to further follow-up
hsa-miR-125b-5p and hsa-miR-16 and identify which candidate
mRNAs involved in epithelial barrier function were being tar-
geted by these two miRNAs. Therefore, we performed bioinfor-
matics analysis of potential miRNA binding sites by miRWalk34
(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/
index.html) and identified two putative miRNA binding sites in
the 30-untranslated region (30-UTR) of the TJ protein encoding
genes CGN (cingulin) and CLDN2 (claudin-2) for hsa-
miR-125b and hsa-miR-16, respectively (figure 2B, see online
supplementary tables S7 and S8). As a first step towards validat-
ing the putative miRNA-based regulation of CGN and CLDN2,
we analysed their protein expression levels in the jejunal mucosa
of patients with IBS-D compared with HC by western blot









Cadherin 1, type 1, E-cadherin (epithelial) CDH1 5220 1.8 0.00001*** 10 283 1.8 0.0002***
CUGBP, Elav-like family member 1 CELF1 524 1.3 0.003** 768 1.5 0.0001***
Cingulin CGN 2188 1.5 0.0001*** 1048 1.4 0.05*
Catenin (cadherin-associated protein), α 1 CTNNA1 2875 1.5 0.002** 4671 1.6 0.007**
Catenin (cadherin-associated protein), β 1 CTNNB1 1998 1.4 0.01* 5892 1.3 0.01**
F11 receptor ( junction adhesion molecule 1) F11R ( JAM1) 3013 1.8 0.0001*** 2429 1.6 0.007**
Junction adhesion molecule 2 JAM2 119 −1.3 0.03* 278 1.2 0.34
Junction adhesion molecule 3 JAM3 70 1.5 0.02* 113 1.3 0.06
Pleckstrin homology domain containing, family A
member 7
PLEKHA7 692 1.8 0.002** 465 1.6 0.01**
p Values are adjusted for multiple testing correction by the Benjamini and Hochberg method. *<0.05; **<0.001; ***<0.0001.
FDR, false discovery rate; RNAseq, RNA sequencing.
Figure 1 Relationships between differentially expressed micro-RNAs (miRNAs) and their putative targets and related canonical pathways and
biological functions (Fx). The list of differentially expressed miRNAs in IBS-D, compared with healthy controls, linked to their approved nomenclature
(http://www.mirbase.org) and fold-change was uploaded into the ingenuity pathway analysis (IPA) application. Target filter analysis was performed
by IPA to get target genes and interactions. Node (target gene/miRNA) and edge (relationship) symbols are described in the figure. The intensity of
the node colour indicates the degree of upregulation (red) or down regulation (green). Genes in uncoloured nodes were not identified as
differentially expressed in our study and were integrated into the computationally generated networks on the basis of the evidence stored in the IPA
knowledge base indicating relevance for this network.
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analysis. In concordance with downregulation of hsa-miR-125b-
5p and hsa-miR-16 (figure 2A), CGN and CLDN2 protein
levels were found to be upregulated in IBS-D (figure 2C). In
addition, no differences in the expression of either hsa-miR-
125b-5p and hsa-miR-16 or their target proteins, CGN and
CLDN2 were found comparing patients with and without func-
tional dyspepsia (see online supplementary table S6).
We next investigated the putative regulation of CGN and
CLDN2 in vitro after overexpression and subsequent inhibition
of hsa-miR-125b-5p and hsa-miR-16. For that purpose, we
selected an established human epithelial cell line, colo320,
which shows endogenous expression of CGN and CLDN2 on
protein level (figure 3A). In order to confirm miRNA-target site
interaction, the candidate hsa-miR-125b-5p or hsa-miR-16 were
transfected into colo320 cells. In addition, both miRNAs were
mutated in order to impair their binding ability to the target site
(figure 3B). Endogenous levels of CGN and CLDN2 were sub-
sequently quantified and compared with that of mock-treated
cells by ICW analysis. Protein levels of both putative target
genes was reduced by respective candidate miRNAs and rescued
in case of particular miRNA mutants (figure 3C). To rule out
unspecific events, we assessed changes in CGN and CLDN2
expression in relation to hsa-miR-510, a miRNA not predicted
to target these proteins. No significant effect on protein levels
was observed for hsa-miR-510, confirming no interaction with
the putative targets (figure 3C).
To further validate miRNA-target gene interactions, colo320
cells were analysed with candidate miRNAs and their mutant
forms (figure 3B) in addition to specific miRNA inhibitors or a
negative inhibitor control. Endogenous protein levels of both,
CGN and CLDN2, were reduced in cells cotransfected with the
negative inhibitor control, while the mutant miRNAs blocked
this effect (figure 3D). On the other hand, endogenous expres-
sion of CGN and CLDN2 were upregulated in case of specific
miRNA inhibitors (figure 3D).
hsa-miR-125b-5p and hsa-miR-16 are involved in the
impairment of TJ structure and epithelial barrier function
by modulating CGN and CLDN2 expression
The functional effect of candidate miRNAs on cellular perme-
ability was assessed using the T84 cell line as a model for
Table 4 Molecular functions associated with the target genes after miRNA-mRNA pairing analysis
Categories Functions annotation FDR Predicted activation state Activation z-score Number of genes
Cell death and survival Cell death of epithelial cells 2.20E-08 ns 0.667 56
Apoptosis of epithelial cells 1.87E-06 ns 0.511 34
Neuronal cell death 7.94E-06 ns 0.872 63
Cell death of epithelial cell lines 4.96E-05 ns 0.285 29
Anoikis 6.52E-04 ns 0.701 12
Cell death of blood cells 1.57E-03 ns 0.76 54
Cellular assembly and organisation Reorganisation of cytoskeleton 8.00E-04 ns 1.166 71
Formation of cytoskeleton 1.23E-03 ns 1.37 36
Organisation of cytoskeleton 5.57E-03 Increased 2.47 93
Outgrowth of neurites 1.46E-04 Increased 3.25 38
Cell development Differentiation of epithelial cells 4.30E-04 ns 1.89 27
Differentiation of epithelial tissue 5.04E-04 Increased 2.001 30
Proliferation of neuronal cells 7.58E-04 Increased 3.181 47
Differentiation of blood cells 8.08E-04 Increased 2.385 58
Proliferation of blood cells 8.41E-04 ns −0.184 64
Proliferation of immune cells 1.83E-03 ns −0.065 59
Epithelial-mesenchymal transition 1.84E-03 ns 1.505 17
Cell-to-cell signalling and interaction Architecture of junctional complexes 4.90E-04 ns 1.224 4
Disorganisation of tight junctions 1.42E-03 ns ns 6
Degradation of intercellular junctions 1.67E-03 ns ns 8
Formation of tight junctions 5.20E-03 ns −0.954 8
Function of tight junctions 6.00E-03 ns 0.816 6
Humoral immune response Quantity of immunoglobulin 1.82E-03 ns −0.269 16
Quantity of B lymphocytes 3.72E-03 ns 0.991 17
Quantity of IgG1 2.57E-03 ns 0.308 9
Quantity of IgM 9.85E-03 ns −0.57 8
Activation z-score indicates probability score of the activation states of molecular functions to determine ‘activated’ (z>0) or ‘inhibited’ predictions (z<0); z-scores greater than 2 or
smaller than −2 can be considered significant. p Values are adjusted for multiple testing by the Benjamini and Hochberg method.
FDR, false discovery rate; mRNA, messenger RNA; miRNA, micro-RNA; ns, not significant.













hsa-miR-125b-5p Inhibited −11.514 2.98E-129 204 (231)
hsa-miR-16-5p Inhibited −4.849 1.4E-22 94 (128)
hsa-miR-29b-3p Inhibited −6.892 2.5E-20 88 (105)
hsa-let-7a-5p Inhibited −5.549 3.89E-19 82 (106)
hsa-miR-128-3p Inhibited −3.192 1.71E-18 66 (98)
hsa-miR-24-3p Inhibited −6.702 9.78E-18 69 (77)
hsa-miR-103-3p Inhibited −2.512 8.50E-17 51 (75)
hsa-miR-92a-3p −1.791 5.39E-09
hsa-miR-155-5p Inhibited −2.17 5.75E-08 31 (47)
hsa-miR-338-3p Inhibited −2.108 1.32E-04 20 (29)
Activation z-score: probability score of the activation states of predicted
transcriptional regulators to determine ‘activated’ (z>0) or ‘inhibited’ predictions
(z<0); z-scores greater than 2 or smaller than –2 are considered significant. p Value
of overlap: overlap between the dataset mRNAs and the mRNAs regulated by the
respective upstream regulator calculated by Fisher’s exact test, p values <0.01 are
considered significant; target molecules in dataset: number of mRNAs that show an
expression direction consistent with the predicted activation state of the respective
upstream regulator (total number of target mRNAs for the respective upstream
regulator).
mRNA, messenger RNA; miRNA, micro-RNA.
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human intestinal epithelial cells. First, miRNA-driven modula-
tion of CGN and CLDN2 was confirmed in T84 cells. Stable
overexpression of hsa-miR-125b-5p and hsa-miR-16 led to
increased expression for both miRNAs, while inhibition by
miRNA sponges led to downregulation of endogenous
hsa-miR-125b-5p and hsa-miR-16 expression (figure 4A).
Endogenous levels of both target proteins, CGN and CLDN2,
were reduced in T84 cells overexpressing the respective candi-
date miRNA (figure 4B). In concordance, cells transfected with
the specific sponges showed increased levels of CGN and
CLDN2 (figure 4B). No changes in ZO1 expression were
detected (figure 4B).
Finally, in order to assess whether modulation of CGN and
CLDN2 by these two miRNAs had an influence on epithelial per-
meability, TEER was measured in T84 cells every day during
7 days. Downregulation of the respective miRNAs led to
increased permeability in each case (decreased TEER) in T84
cells, while particular miRNA overexpression caused the oppos-
ite effect (figure 4C). In addition, influence on TJ structure was
assessed by analysing ZO1 distribution in polarised T84 cells
(7 days postseeding). While overexpression of hsa-miR-125b-5p
and hsa-miR-16 did not affect the characteristically continuous
belt-like pattern of ZO1 staining around the apical membrane of
T84 cells, inhibition induced a highly disorganised ZO1 staining
Figure 2 Expression analysis of candidate micro-RNAs (miRNAs) and their potential target proteins in IBS-D versus healthy controls (HC) jejunal
samples. (A) Quantitative PCR validation of differentially expressed miRNAs in patients with IBS-D. To obtain the fold-change value for each sample
the ratio between target miRNA and the average of reference genes was calculated for each sample and then normalised to the average of the
healthy group. Groups were compared using the non-parametric Mann-Whitney U test. **p<0.01. (B) miRNA binding sites in the 30-untranslated
region (30-UTR) of the barrier function-related genes cingulin (CGN) and claudin-2 (CLDN2) identified by TargetScan. (C) Claudin-2 and cingulin
protein expression in the jejunal mucosa. Protein expression was measured by western blot in patients with IBS-D and healthy control subjects.
Protein fold-change was calculated for each sample with reference to the average of the target protein to GAPDH ratio of the healthy control group.
Comparisons were performed by the Mann-Whitney U test (p values shown).
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pattern for each miRNA (figure 5A). Disruption of TJ structure
was confirmed by increased number of cell nuclei contained in
complete ZO1 belts after inhibition of both miRNAs indicating a
decrease in ZO1 belt structures/impaired barrier (figure 5B).
Major clinical and histopathological features of patients
with IBS-D correlate with hsa-miR-125b-5p and hsa-miR-16
and their target genes, CGN and CLDN2
To assess the potential clinical relevance of our findings, we
applied the Spearman’s correlation rho to pooled data of
patients and HC. Both miRNAs studied negatively correlated
with bowel habits (see online supplementary table S9), while
hsa-miR-125b-5p also correlated with the frequency of abdom-
inal pain (see online supplementary table S9). Conversely, CGN
and CLDN2 protein expression positively correlated with bowel
habits. On the other hand, chronic stress levels measured by the
Holmes-Rahe scale did not correlate with the expression levels
of these two miRNAs or their target proteins (see online
supplementary table S10). Yet, we found a negative correlation
between the expression of miRNAs and perceived stress and
Figure 3 hsa-miR-125b-5p and hsa-miR-16 target cingulin and claudin-2, respectively. (A) Endogenous claudin-2 and cingulin protein expression
in epithelial cell lines. Protein expression was measured by western blot in colo320 and HEK293 cells; a jejunum sample was used as a positive
control. (B) Wild-type and mutant sequences of the pEP-miR vectors used. (C) In-Cell Western (ICW) was applied to measure endogenous protein
expression after cotransfecting colo320 cells with either wild-type or mutant pEP-miR vectors and the pEP-miR null vector as a control miR. A
pEGFP-C1 construct was cotransfected as a transfection and normalisation control. Quantification of endogenous proteins was measured and
analysed according to the Odyssey Infrared Imaging System of LI-COR. (D) ICW was applied to measure endogenous protein expression after
cotransfecting colo320 cells with either wild-type or mutant pEP-miR expressing vectors and specific mirVANA inhibitors (50 nM for miR-125b
inhibitor and 150 nM for miR-16 inhibitor) or negative controls. pEP-miR-510 was used as a control miRNA. A pEGFP-C1 construct was
cotransfected as a transfection and normalisation control. Quantification of endogenous proteins was measured and analysed according to the
Odyssey Infrared Imaging System of LI-COR. Graphs represent results from six independent experiments. Data are expressed as mean±SD.
Comparisons were performed by two-way analysis of variance followed by Bonferroni post-tests. *p<0.05; **p<0.01; ***p<0.001. ctrl, control.
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depression, measured by the Cohen and the Becks scales,
respectively (see online supplementary table S10).
Moreover, patients with IBS-D showed increased mast cell
numbers (IBS-D: 26.46±12.68; HC: 17.80±9.52 CD117+
cells/hpf; p=0.0007). Downregulation of hsa-miR-125b-5p and
hsa-miR-16 negatively correlated with mast cell numbers (figure
6A); while CGN and CLDN2 protein expression positively
correlated with numbers of mast cells (figure 6B).
DISCUSSION
In this study, we provide evidence that the modulation of the
intestinal epithelial barrier function in IBS-D involves both tran-
scriptional and post-transcriptional mechanisms, including
miRNAs hsa-miR-125b-5p and hsa-miR-16 as master regulators
in controlling the expression of specific TJ proteins. Moreover,
expression of both miRNAs and their target proteins correlate
with major symptoms and mast cell hyperplasia, supporting the
involvement of these cells in the impairment of intestinal epithe-
lial barrier function as a central molecular mechanism in this
disease. The data gained in this study, together with previous
reports of other groups and our own research line contribute to
further delineate the current view of IBS-D origin in which the
organic basis of this disorder is substantiated by a heterogeneous
network of immunological responses, involving hyperactivation
of mast cells, T and B lymphocytes and impaired epithelial
apical junctional structure and its association with intestinal
barrier dysfunction and cardinal symptoms (figure 7).
The essential role of miRNAs in the modulation of protein
expression in the intestinal epithelium has been firmly estab-
lished.24 35–37 In line with this, altered miRNA profiles have
been reported in intestinal diseases including IBS.22 23 38 39
Now, we show additional evidence on deregulation of miRNA
expression in the jejunum of patients with IBS-D. In fact,
recently a comprehensive study assessed miRNA profiles in dif-
ferent organs of the human body and revealed different expres-
sion profiles of miRNAs in small versus large intestine.40 Of
note, none of the previously reported miRNAs22 38 39 were con-
firmed in our study, probably due to gut region-specific differ-
ences. This represents the major drawback of comparisons of
data gained in different studies on various regions of the gut
owing to distinct functions of the proximal and distal gut.
Consequently, differential expression of the same individual
molecules (ie, genes, proteins or miRNAs) should not be neces-
sarily expected along the whole intestine. This issue is well
reflected by the discrepancies observed between different studies
in IBS.6 41 Nonetheless, it is remarkable that molecular changes
observed in earlier studies hit similar pathways leading to
impaired epithelial barrier function and increased intestinal
Figure 4 Epithelial barrier function is impaired by hsa-miR-16 and hsa-miR-125b-5p in T84 cells. T84 cells were created that stably expressed
hsa-miR-16 or hsa-miR-125b-5p overexpression or downregulation constructs (sponges). (A) Stable cells lines were evaluated for miRNA expression by
qPCR. Values are normalised to control cells. Graphs represent results from three independent experiments. Data are expressed as mean±SD. Comparisons
were performed by the Mann-Whitney U test versus control (Ctrl) miR cells. *p<0.05. (B) Stable cell lines were evaluated for cingulin (CGN), claudin-2
(CLDN2) and zonula occludens 1 (ZO1) expression by western blot. Actin was used as a loading control. Representative image of a triplicate experiment is
shown. (C and D) Stable cell lines were seeded onto transwell inserts and epithelial barrier function was monitored over time by measuring transepithelial
electrical resistance after overexpression (C) or downregulation (D). Graphs represent results from three independent experiments. Data are expressed as
mean±SD. Comparisons were performed by two-way analysis of variance followed by Bonferroni post-tests. ***p<0.001.
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permeability. Another factor contributing to discrepancies
between published data is represented by the application of dif-
ferent methodology and data analysis pipelines. Currently, no
gold standard for miRNA profiling exists. Due to their short
sequences (22–25 nucleotides) and high degree of homology
between miRNA family members, miRNA detection is technic-
ally challenging. A recent comparative study on established
miRNA profiling platforms revealed variation in their reproduci-
bility, sensitivity and accuracy.42 To overcome these limitations,
we combined the profiling data from two of the best performing
miRNA platforms42 and validated our findings applying a third
method (qPCR). In addition, this is the first study on IBS inte-
grating miRNA and mRNA profiling data. This paired analysis
led to identification of a set of miRNA targets differentially
expressed in the jejunum of patients with IBS-D. Notably, 65%
of the pathways associated with the RNAseq data obtained in
this analysis were also found in our previous microarray study,13
including those related to the modulation of epithelial barrier
function through TJs and caveolar-mediated endocytosis. The
discrepancy between datasets may be attributed to the different
methods used: microarrays which are restricted to detection of
specific isoforms versus RNA sequencing that detects the whole
transcriptome and more accurately fetches the repertoire of
gene isoforms. The data obtained here, therefore, reinforces and
extends our results using a different profiling technique on a dif-
ferent set of patients.1 13 14 We decided to focus on candidates
related to the modulation of apical junctional complexes (ie, TJ,
caveolar-mediated endocytosis and actin cytoskeleton signalling)
to keep in line with our major research hypothesis and because
other studies reporting on miRNA regulation in IBS also
showed differentially regulated candidates involved in the epi-
thelial barrier function.22 38 In addition, other functions and
pathways were identified in our analysis with higher significance,
like epithelial cell death and apoptosis categories which, in turn,
may also relate to dysfunctional epithelial barrier associated
with deregulation of miRNA activity in the gut.24 Candidates
belonging to these functions and how they are modulated
by miRNAs in IBS-D, indeed, merit further assessment in the
future.
The two most promising miRNA candidates, hsa-miR-
125b-5p and hsa-miR-16, were chosen based on IPA analysis of
miRNA and mRNA profiles. The 30-UTR of genes from the TJ
signalling pathway were systematically scanned in order to find
binding sites for these two miRNAs. Results of the most com-
prehensive miRNA search tool miRWalk showed two putative
binding sites in CGN for hsa-miR-125b-5p and in CLDN2 for
hsa-miR-16 in four and five out of five prediction tools, respect-
ively. CGN localises in the cytoplasmic surface of TJs of intes-
tinal epithelial cells43 and interacts with the actomyosin
cytoskeleton and ZO proteins.44 Cingulin does not seem to be
required for the basic structure and canonical function of TJ.45–
47 However, it contributes to modulating gene expression of TJ
proteins during epithelial differentiation45 through a yet not
completely understood mechanism involving RHOA activity46
Figure 5 Tight junctions structure is impaired by hsa-miR-16 and hsa-miR-125b-5p. T84 cells were created that stably expressed hsa-miR-16 or
hsa-miR-125b-5p overexpression or downregulation constructs. Cells were seeded onto transwell inserts and allowed to polarise for 7 days. (A)
7 days postseeding cells were fixed and stained for the tight junction protein zonula occludens 1 (ZO1) (red) and cell nuclei were stained for
40,6-diamidino-2-phenylindole (DAPI) (blue). (B). Nuclei per complete ZO1 were quantified. Graphs represent results from three independent
experiments. Fifty fields per sample were counted. Comparisons were performed by the Mann-Whitney U test versus control cells. ***p<0.001.
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and GATA4 expression.48 In addition, CGN is a predicted target
for HNF4A, a transcription factor regarded as key regulator of
intestinal differentiation.49 Therefore, the activity of CGN in
modulating TJ dynamics must be viewed in the context of a
wider signalling network that is likely to be differentially modu-
lated under different physiological and pathological conditions.
CGN protein overexpression and, consistently, hsa-miR-125b-
5p downregulation was confirmed in IBS-D samples. Fine-
tuning the activity of CGN and its functional network by
miRNAs and its implications for intestinal barrier dysfunction
related to intestinal inflammation and, particularly, IBS-D
remains to be investigated. Remarkably, the claudin family is
responsible for modulating passage through the paracellular
route and alterations in expression and distribution have been
associated with several intestinal diseases.50 Recent reports have
shown the implication of claudin deregulation in epithelial
barrier function in IBS.1 38 51 52 Our own previous data
showed increased claudin-2 protein levels in the jejunum of
patients with IBS-D as part of the molecular mechanism that
may account for disrupted TJ ultrastructure and increased
permeability.1 Now we confirmed the upregulation of
claudin-2 in a different set of patients with IBS-D and valid-
ate it as a real target for hsa-miR-16 which, consistently, is
downregulated in IBS-D samples. In addition, we used a cell
model to mimic the situation described in patients with
IBS-D (downregulation of hsa-miR-16/hsa-miR-125b-5p and
upregulation of CLDN2/CGN) showing the functional dis-
ruption of the epithelial barrier as a consequence and, there-
fore, providing evidence on the impact of miRNA
modulation of specific TJ proteins in the increased intestinal
permeability that has been consistently described in patients
with IBS-D in earlier studies.53
Interestingly, mast cell numbers correlated positively with
CGN and CLDN2 protein expression and negatively with their
respective targeting miRNAs. On the other hand, miRNA altera-
tions correlated negatively with bowel habits and with the acute
stress response and depression levels. The negative correlations
found in our study indicate that those patients showing less
expression levels of the respective miRNA and consequently,
increased target protein expression and disturbed barrier, are suf-
fering from increased mast cell counts and higher levels of stress
and depression. We and others have previously reported that
stress can deeply affect permeability via mast cell activation.54 55
Remarkably, several miRNAs, including hsa-miR-125b-5p, have
been found to be highly expressed in exosomes from mast cell
lines.56 As exosomes are well known to participate in cell-to-cell
communication delivering their contents to target cells, it could
be speculated that mast cell-mediated modulation of epithelial
permeability could be driven by direct delivery of high amounts
of hsa-miR-125b-5p (and other miRNAs) to epithelial cells in
homeostatic conditions. Disruption of homeostasis would then
trigger downregulation of hsa-miR-125b expression. Studies
aimed at deciphering this interesting connection would be key to
further determine the role of miRNAs in mucosal inflammation
and barrier disruption. However, whether miRNA deregulation,
mast cell hyperactivity and impaired barrier function are the
cause or the consequence will still remain to be determined. In
addition, evidence collected to date has shown that miRNA
expression is altered in patients suffering from depression and
anxiety and in animal models of early life, restraint and
Figure 6 Statistical correlations. (A) Correlation between mast cell numbers and claudin-2 and cingulin protein expression in the jejunal mucosa
of IBS-D and healthy controls. Spearman’s correlation rho was calculated in the pooled dataset of healthy controls (n=15) and patients with IBS-D
(n=23). (B) Correlation between mast cell numbers and hsa-miR-16 and hsa-miR-125b-5p expression in the jejunal mucosa of IBS-D and healthy
controls. Spearman’s correlation rho was calculated in the pooled dataset of healthy controls (n=18) and patients with IBS-D (n=14). CD117+/hpf,
number of mast cells per high power field, mast cells were measured by staining with CD117.
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unpredictable chronic mild stress.57–60 Of note, hsa-miR-16 has
been reported to regulate other important genes of the serotoner-
gic system, for example, the serotonin reuptake transporter gene
SLC6A4, a key regulator of serotonin availability in the nervous
system and gut epithelium.58 In the central nervous system,
hsa-miR-16 had been reported to mediate depression behaviours
through regulation of SLC6A458; furthermore, a mechanistic
connection to depression through neurogenesis pathways was
observed61 and hsa-miR-16 has recently been linked to anxiety.62
Taken together, our results suggest that miRNA-driven modula-
tion of TJ proteins may cause epithelial barrier dysfunction in
the jejunum of patients with IBS-D that could explain, at least in
part, the bowel dysfunction characteristic of this disease.
However, caution is advised when interpreting the functional
consequences of these data as correlations obtained are only
modest and they do not imply causation and other mechanisms
can be playing a role to explain our observations. In addition,
data involving miRNAs in the modulation of mast cell biology
are still scarce; therefore, the precise mechanism linking mast
cells, miRNA deregulation and development of symptoms needs
further exploration.
We would like to acknowledge that this study was conceived
as an exploratory study and, therefore, no prior power calcula-
tion was performed, yet sample size was in the same range of
similar reports12 22 38 39. In addition, although we isolated
RNA, miRNA and protein from the same sample, we could not
get enough material to perform all different analyses in all parti-
cipants. Therefore, the number of samples for some of the
experiments was relatively small. However, we followed a very
exhaustive and stringent phenotyping protocol for both patients
and controls which provided us with a highly homogeneous
cohort. In addition, a major strength of our study is that for
functional validation of results we analysed endogenous levels
of the target proteins instead of using artificial reporter systems
that could bias the results.
In summary, we show specific miRNA regulation of TJ proteins
associated with major clinical symptoms in IBS-D. This study
together with previous results, come to reinforce our line of
research where organicity is evidenced in IBS-D, mainly affect-
ing gut epithelial barrier integrity. Defining the complex array
of interactions and modulations of miRNAs with apical junc-
tional proteins will pave the way for potential diagnostic and
therapeutic interventions that would reinforce the intestinal
epithelial barrier function, potentially restabilising intestinal
homeostasis.
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